RxDoctor Payments Data

Scott Gayley, MD

Family Medicine · Salina, KSNPI 1154357929

Payments from drug & device makers

$173in general payments, 2019–2025

Across 11 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$61
  • Novartis$28
  • AbbVie$25
  • Esperion Therapeutics, Inc.$22
  • Novo Nordisk$14
  • Abbott$12
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$173100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK4$61
Novartis2$28
AbbVie1$25
Esperion Therapeutics, Inc.1$22
Novo Nordisk1$14
Abbott1$12
Pfizer1$11

How this compares

$173 in reported general payments places this provider in the 30th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$120,596
Medicare patients
311
Services billed
3,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide81$105,270
EliquisApixaban172$96,715
OzempicSemaglutide89$91,438
OtezlaApremilast12$57,801
MounjaroTirzepatide35$37,560
FarxigaDapagliflozin Propanediol23$23,566
RybelsusSemaglutide15$16,817
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$14,400
JardianceEmpagliflozin20$13,701
ShingrixVaricella-Zoster Ge/As01b/Pf56$12,405
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$12,131
SymbicortBudesonide/Formoterol Fumarate42$9,794
ArexvyRsvpref3 Antigen/As01e/Pf30$9,037
JanuviaSitagliptin Phosphate15$8,826
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate47$7,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$108,254104 claims
PfizerEliquis, Dilantin$11$98,500184 claims
GSKShingrix, Arexvy$61$21,44186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Salina

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →